GB201701968D0 - Gene therapy - Google Patents

Gene therapy

Info

Publication number
GB201701968D0
GB201701968D0 GBGB1701968.8A GB201701968A GB201701968D0 GB 201701968 D0 GB201701968 D0 GB 201701968D0 GB 201701968 A GB201701968 A GB 201701968A GB 201701968 D0 GB201701968 D0 GB 201701968D0
Authority
GB
United Kingdom
Prior art keywords
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1701968.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Manchester
Original Assignee
University of Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Manchester filed Critical University of Manchester
Priority to GBGB1701968.8A priority Critical patent/GB201701968D0/en
Publication of GB201701968D0 publication Critical patent/GB201701968D0/en
Priority to EP18705462.2A priority patent/EP3579849B1/en
Priority to EP21187825.1A priority patent/EP3960188B1/en
Priority to ES21187825T priority patent/ES3035262T3/es
Priority to ES18705462T priority patent/ES2895263T3/es
Priority to PCT/GB2018/050347 priority patent/WO2018146473A1/en
Priority to JP2019542703A priority patent/JP7237364B2/ja
Priority to US16/484,311 priority patent/US11701390B2/en
Priority to US18/086,719 priority patent/US20230390340A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1701968.8A 2017-02-07 2017-02-07 Gene therapy Ceased GB201701968D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1701968.8A GB201701968D0 (en) 2017-02-07 2017-02-07 Gene therapy
EP18705462.2A EP3579849B1 (en) 2017-02-07 2018-02-07 A nucleic acid comprising ids gene sequence and a tandem repeat of apolipoprotein e gene sequence
EP21187825.1A EP3960188B1 (en) 2017-02-07 2018-02-07 A nucleic acid comprising ids gene sequence and a tandem repeat of apolipoprotein e gene sequence
ES21187825T ES3035262T3 (en) 2017-02-07 2018-02-07 A nucleic acid comprising ids gene sequence and a tandem repeat of apolipoprotein e gene sequence
ES18705462T ES2895263T3 (es) 2017-02-07 2018-02-07 Un ácido nucleico que comprende la secuencia de genes IDS y una repetición en tándem de la secuencia de genes de apolipoproteína E
PCT/GB2018/050347 WO2018146473A1 (en) 2017-02-07 2018-02-07 Gene therapy
JP2019542703A JP7237364B2 (ja) 2017-02-07 2018-02-07 遺伝子治療
US16/484,311 US11701390B2 (en) 2017-02-07 2018-02-07 Gene therapy
US18/086,719 US20230390340A1 (en) 2017-02-07 2022-12-22 Gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1701968.8A GB201701968D0 (en) 2017-02-07 2017-02-07 Gene therapy

Publications (1)

Publication Number Publication Date
GB201701968D0 true GB201701968D0 (en) 2017-03-22

Family

ID=58462471

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1701968.8A Ceased GB201701968D0 (en) 2017-02-07 2017-02-07 Gene therapy

Country Status (6)

Country Link
US (2) US11701390B2 (enExample)
EP (2) EP3960188B1 (enExample)
JP (1) JP7237364B2 (enExample)
ES (2) ES2895263T3 (enExample)
GB (1) GB201701968D0 (enExample)
WO (1) WO2018146473A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
KR20250110842A (ko) 2022-11-01 2025-07-21 에라스무스 유니버시티 메디컬 센터 로테르담 대사질환을 위한 유전자 요법 구성체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
JP2007513188A (ja) 2003-12-04 2007-05-24 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リソソーム蓄積症の処置のための組成物および方法
US10227387B2 (en) 2011-05-18 2019-03-12 Children's Hospital Medical Center Targeted delivery of proteins across the blood-brain barrier
RU2014126482A (ru) 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение
EP3218000A2 (en) * 2014-11-10 2017-09-20 Alexion Pharmaceuticals, Inc. Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof

Also Published As

Publication number Publication date
EP3579849B1 (en) 2021-09-08
EP3960188B1 (en) 2025-04-02
EP3960188A1 (en) 2022-03-02
WO2018146473A1 (en) 2018-08-16
JP2020506714A (ja) 2020-03-05
ES3035262T3 (en) 2025-09-01
US20200000854A1 (en) 2020-01-02
EP3579849A1 (en) 2019-12-18
US20230390340A1 (en) 2023-12-07
JP7237364B2 (ja) 2023-03-13
US11701390B2 (en) 2023-07-18
ES2895263T3 (es) 2022-02-18

Similar Documents

Publication Publication Date Title
IL304084B1 (en) Gene healing
IL268894A (en) Medical RNA
IL320674A (en) Garden care
GB201707153D0 (en) Therapy
LT3612237T (lt) Genų terapija
GB201719646D0 (en) Therapy
GB201708663D0 (en) Therapy
GB201407322D0 (en) Gene therapy
IL279685A (en) Gene therapy
GB201609597D0 (en) Therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201802326D0 (en) Gene therapy
GB201817470D0 (en) Gene therapy
GB201701968D0 (en) Gene therapy
GB201707500D0 (en) New therapy
GB201513151D0 (en) Functional gene replacement therapy
HK40100628A (zh) 基因疗法
HK40096184A (zh) 基因疗法
HK40095843A (zh) 基因疗法
GB201820982D0 (en) Gene Therapy
GB201704634D0 (en) Gene therapy
GB201811541D0 (en) Gene therapy
GB201801511D0 (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)